Anthem Biosciences FY26 PAT rises 31% to Rs 592 crore
Anthem Biosciences reported a 31% YoY increase in PAT to Rs. 592 crores for FY26, with total revenue growing 18% to Rs. 2,280 crores. Q4 was the highest revenue quarter on record, with consolidated revenues reaching Rs. 611 crores. The company plans to invest Rs. 1,200 crores in Unit 4 expansion over FY27 and FY28 to add significant manufacturing capacity.
*this image is generated using AI for illustrative purposes only.
Anthem Biosciences has reported its financial results for the quarter and year ended March 31, 2026. The company concluded the fiscal year with a strong performance, posting a profit after tax (PAT) of Rs. 592 crores, a growth of 31% over the previous year. Net profit margins stood at 26% for the full year.
Financial Performance
For the full year FY26, the company achieved a total revenue of Rs. 2,280 crores, an 18% increase compared to the prior year. Consolidated revenue from operations reached Rs. 2,124 crores. The CRDMO business was the primary contributor, generating Rs. 1,773 crores, which represents 83% of the total revenue and reflects an 18% growth. Specialty ingredients contributed Rs. 352 crores.
The fourth quarter of FY26 marked the highest revenue quarter in the company's history. Consolidated revenues for Q4 reached Rs. 611 crores, a year-on-year increase of 26%. The CRDMO segment delivered Rs. 513 crores in revenue for the quarter, growing by 31%, while specialty ingredients recorded Rs. 98 crores. Quarterly PAT stood at Rs. 190 crores, a surge of 130% on a YoY basis with margins of 28.7%.
| Metric | FY26 Value | YoY Growth |
|---|---|---|
| Total Revenue | Rs. 2,280 crores | 18% |
| Revenue from Operations | Rs. 2,124 crores | - |
| PAT | Rs. 592 crores | 31% |
| EBITDA | Rs. 990 crores | 31% |
| Net Cash Position | Rs. 1,375 crores | - |
Operational Highlights and Outlook
Management highlighted that the impact of destocking is largely behind the company, with expectations of restocking driving future growth. The company's EBITDA for the year was Rs. 990 crores, with margins expanding to 43.4%. Looking ahead, the company outlined significant capital expenditure plans focused on expanding its manufacturing capabilities.
The board has approved a major expansion plan for Unit 4, which will be the company's largest project to date. The company plans to invest approximately Rs. 1,200 crores across FY27 and FY28 for Phase 1 of this expansion. This phase is expected to add 365 kiloliters of custom synthesis capacity and 100 kiloliters of fermentation capacity. The capex for the upcoming year is anticipated to be around Rs. 700 crores. Management stated that capacity additions in Unit 2 and Unit 3 provide sufficient headroom until Unit 4 becomes operational.
How will the Rs. 1,200 crore Unit 4 expansion impact Anthem Biosciences' competitive positioning in the global CRDMO market once it becomes operational?
Which therapeutic areas or client geographies is Anthem Biosciences targeting to sustain the 18-31% revenue growth trajectory beyond FY28?
With restocking expected to drive future growth, how vulnerable is Anthem Biosciences to another destocking cycle if global pharma inventory management patterns shift again?
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
